Vireo Growth (VREOF) Enterprise Value (2020 - 2026)
Vireo Growth (VREOF) reported Enterprise Value of -$153.2 million for Q1 2026, down 74.19% on a YoY basis from -$593.5 million in Q1 2025, and down 7.28% sequentially from -$142.8 million in Q4 2025.
Vireo Growth (VREOF) Enterprise Value (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Enterprise Value data on file, last reported at -$153.2 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 74.19% year-over-year to -$153.2 million; the trailing twelve-month figure through Mar 2026 stood at -$153.2 million (down 74.19% YoY), and the FY2025 full-year result was -$142.8 million, down 52.12% from the prior year.
- Enterprise Value eased to -$153.2 million in Q1 2026, from -$142.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$7.3 million in Q3 2024 to a low of -$153.2 million in Q1 2026.
- A 5-year average of -$49.6 million and a median of -$17.0 million in 2022 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value jumped 78.79% in 2022 and plunged 1528.49% in 2025, its largest moves.
- Tracing VREOF's Enterprise Value over 5 years: stood at -$15.1 million in 2022, then dropped by 18.17% to -$17.9 million in 2023, then slumped by 424.36% to -$93.9 million in 2024, then plunged by 52.12% to -$142.8 million in 2025, then retreated by 7.28% to -$153.2 million in 2026.
- Business Quant data shows VREOF's Enterprise Value at -$153.2 million in Q1 2026, -$142.8 million in Q4 2025, and -$118.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -4.05 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -2.15 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -1.32 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -428.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -153.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -153.20 Mn |
| Dec 31, 2025 | -142.80 Mn |
| Sep 30, 2025 | -118.55 Mn |
| Jun 30, 2025 | -100.41 Mn |
| Mar 31, 2025 | -87.95 Mn |
| Dec 31, 2024 | -93.87 Mn |
| Sep 30, 2024 | -7.28 Mn |
| Jun 30, 2024 | -11.23 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Dec 31, 2023 | -17.90 Mn |
| Sep 30, 2023 | -13.30 Mn |
| Jun 30, 2023 | -11.35 Mn |
| Mar 31, 2023 | -10.35 Mn |
| Dec 31, 2022 | -15.15 Mn |
| Sep 30, 2022 | -21.84 Mn |
| Jun 30, 2022 | -16.97 Mn |
| Mar 31, 2022 | -8.60 Mn |
| Dec 31, 2021 | -15.16 Mn |
| Sep 30, 2021 | -11.78 Mn |
| Jun 30, 2021 | -20.83 Mn |